Background
Hemorrhage is the leading cause of preventable trauma-related deaths. We have previously shown that treatment with Tubastatin A (Tub A), a histone deacetylase (HDAC) 6 inhibitor, can improve survival in a rodent model of septic shock. The aims of present study were to determine whether selective inhibition of HDAC 6 can promote survival in a model of hemorrhagic shock (HS).
Methods
Experiment I (survival study): Wistar-Kyoto rats were subjected to hemorrhagic shock (55% volume blood loss), followed by intraperitoneal injection of either Tub A (70 mg/kg) dissolved in dimethyl sulfoxide (DMSO), or DMSO only (vehicle group) (n=8/group). Survival was monitored for 24 hours. Experiment II (physiologic study): Rats were subjected to a sub-lethal HS (40% blood loss), followed by the same treatment with Tub A (treatment group) or DMSO only (vehicle group, n=5/group). All animals were sacrificed 6 hours after hemorrhage, and heart and liver tissues were harvested. Sham animals were not subjected to hemorrhage and treatment (sham group, n=5/group). Cardiac mitochondria were isolated to study the pyruvate dehydrogenase (PDH; an essential enzyme for ATP production) activity. Liver tissue lysates were analyzed for markers of apoptosis (cytochrome c, cleaved caspase-3), and inflammation (high mobility group box 1 (HMGB1) by Western blotting.
Results
Severe hemorrhagic shock (55% blood loss) was associated with 75% mortality, which was significantly improved by Tub A treatment (37.5% mortality in 24 hours; P=0.048). Tub A also significantly enhanced the cardiac PDH activity compared to the vehicle group, while suppressing the hepatic HMGB1 expression, cytochrome c release, and caspase-3 activation.
Conclusions
Our study has demonstrated for the first time that selective inhibition of HDAC6 can improve survival in a rodent model of HS. The potential mechanisms include enhanced PDH activity, decreased inflammatory drive, and attenuated cellular apoptosis.